{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dasatinib+100+MG&page=2",
    "query": {
      "intervention": "Dasatinib 100 MG",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 73,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dasatinib+100+MG&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dasatinib+100+MG&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T01:36:44.289Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00816283",
      "title": "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "cytogenetic analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2008-09",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-07-17",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Pasadena, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00816283"
    },
    {
      "nct_id": "NCT01218477",
      "title": "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "BMS-833923",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2011-01",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-06-17",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218477"
    },
    {
      "nct_id": "NCT04996160",
      "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia, Pediatric",
        "Relapsed Acute Lymphoblastic Leukemia",
        "Refractory Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tanja Andrea Gruber",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-07-09",
      "completion_date": "2023-10-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04996160"
    },
    {
      "nct_id": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2007-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 17,
      "location_summary": "Anaheim, California • Loma Linda, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00982488"
    },
    {
      "nct_id": "NCT05422885",
      "title": "Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Aging"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Quercetin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lewis Lipsitz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-05-20",
      "completion_date": "2024-01-24",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422885"
    },
    {
      "nct_id": "NCT01254864",
      "title": "Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 190,
      "start_date": "2011-03-16",
      "completion_date": "2023-12-07",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01254864"
    },
    {
      "nct_id": "NCT07270120",
      "title": "Senolytics for Secondary Progressive MS",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis (MS) Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "Dasatinib and quercetin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-01-15",
      "completion_date": "2028-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07270120"
    },
    {
      "nct_id": "NCT00696072",
      "title": "Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2008-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 27,
      "location_summary": "Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00696072"
    },
    {
      "nct_id": "NCT00767520",
      "title": "Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Exemestane + Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Exemestane + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2009-02",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 4,
      "location_summary": "Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00767520"
    },
    {
      "nct_id": "NCT00787852",
      "title": "A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47",
          "type": "DRUG"
        },
        {
          "name": "Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-03",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-07-30",
      "last_synced_at": "2026-10-09T01:36:44.289Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787852"
    }
  ]
}